This is true, but at least in drug development (where I have some experience), no two studies are alike. Even when a drug company runs two phase 3 trials (like they are supposed to in order to secure FDA approval), the design or execution varies enough that if one fails, it doesn't necessarily suggest that the other one is a false positive.
